Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
newtelegraphng7h
Diabetes Day: Merck Foundation Gives 830 Scholarships To Doctors From 52 Countries
ShareIn commemoration of the 2024 World Diabetes Day, Merck Foundation, the philanthropic arm of Merck KGaA Germany, has ...
BioPharma Dive11h
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
STAT12h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
STAT14h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Yale Daily News1d
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Asuka Koda covers the Yale ...
Merck KGaA: Phase III Trial Of Pimicotinib In Tenosynovial Giant Cell Tumor Meets Primary Endpoint
Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...
Business Insider2d
Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial
No new safety signals were identified. Alexion, AstraZeneca Rare Disease will share these data with regulatory authorities and present these data at a forthcoming medical meeting. AstraZeneca and ...